San Francisco, CA61 Active Studies

Pulmonary Hypertension Clinical Trials in San Francisco, CA

Find 61 actively recruiting pulmonary hypertension clinical trials in San Francisco, CA. Connect with local research sites and explore new treatment options.

61
Active Trials
44
Sponsors
18,392
Enrolling

Recruiting Pulmonary Hypertension Studies in San Francisco

About Pulmonary Hypertension Clinical Trials in San Francisco

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 61 pulmonary hypertension clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 18,392 participants. Research is being sponsored by Pulmonary Hypertension Association, Inc., St. Joseph's Hospital and Medical Center, Phoenix, The American Porphyrias Expert Collaborative and 41 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in San Francisco — FAQ

Are there pulmonary hypertension clinical trials in San Francisco?

Yes, there are 61 pulmonary hypertension clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 61 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated October 16, 2026 from ClinicalTrials.gov